Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.53 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9672168 | 0.93 | ALDH1A1 (0.65) | ALDH1A1LMNAHPGDHSD17B10TSHR | |
| SCHEMBL5359112 | 0.86 | GAA (0.59) | ALDH1A1LMNAHPGDHSD17B10TSHR | |
| SCHEMBL10001053 | 0.85 | ALDH1A1 (0.56) | ALDH1A1LMNAHPGDHSD17B10TSHR | |
| SCHEMBL9139821 | 0.85 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDHSD17B10TSHR | |
| SCHEMBL10001054 | 0.84 | ALDH1A1 (0.54) | ALDH1A1LMNAHPGDHSD17B10TSHR | |
| SCHEMBL1663817 | 0.83 | LMNA (0.87) | ALDH1A1LMNAHPGDHSD17B10TSHR | |
| SCHEMBL15989535 | 0.82 | ALDH1A1 (0.65) | ALDH1A1LMNAHPGDHSD17B10TSHR | |
| SCHEMBL3503405 | 0.82 | KDM4E (1.00) | ALDH1A1LMNAHPGDHSD17B10TSHR | |
| SCHEMBL7152871 | 0.80 | ALDH1A1 (0.78) | ALDH1A1LMNAHPGDHSD17B10TSHR | |
| SCHEMBL9831538 | 0.80 | LMNA (0.71) | ALDH1A1LMNAHPGDHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6306203-B1 | FOR USE IN INK JET PRINTING, INCLUDING PIEZOELECTRIC INK JET PRINTING AND ACOUSTIC INK JET PRINTING | XEROX CORPORATION | 2001-10-23 | — | — | US | claimed |
| US-4271260-A | POSITIVE IMAGES OBTAINED USING A SUPPORTED LAYER OF AN ALKALI-SOLUBLE POLYMERIC BINDER, A HEXAARYLBIIMIAZOLE, AND A CARBOXY-, CARBONYL-, OR CYANO-SUBSTITUTED DIHYDROPYRIDINE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-06-02 | — | — | US | claimed |
| US-4243741-A | HEXAARYLBIIMIDAZOLE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-01-06 | — | — | US | claimed |
| CN-110483563-B | Preparation method and application of novel ionic beta-naphthoic aldehyde Schiff base zirconium complex | 山西医科大学 | 2021-12-28 | — | — | CN | disclosed |
| EP-2842559-A2 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | Chimerix, Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-1868628-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF POXVIRUS INFECTIONS | CHIMERIX INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8642577-B2 | Compounds, compositions and methods for the treatment of poxvirus infections | CHIMERIX, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110015149-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS | CHIMERIX, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20070003608-A1 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | CHIMERIX, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070003516-A1 | Compounds, compositions and methods for the treatment of poxvirus infections | EMERGENT BIODEFENSE OPERATIONS LANSING LLC | 2007-01-04 | — | — | US | disclosed |
| EP-1007034-B1 | COMPOSITIONS CONTAINING BERGAMOTTIN FOR INCREASING THE ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS | WARNER LAMBERT CO (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-1999008676-A1 | COMPOSITIONS CONTAINING BERGAMOTTIN FOR INCREASING THE ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| US-5567592-A | IDENTIFYING COMPOUNDS USEFUL FOR INCREASING BIOAVAILABILITY OF DRUG IN MAMMAL | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-10-22 | — | — | US | disclosed |
| US-5399458-A | Process for making images employing a toner which has a tackiness that can be increased by actinic radiation | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-03-21 | — | — | US | disclosed |
| US-4716095-A | PRETREATMENT WITH ACID | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-12-29 | — | — | US | disclosed |
| US-4698293-A | Process for forming positive tonable images using a photosensitive material containing at least 1,4-dihydropyridine | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-10-06 | — | — | US | disclosed |
| EP-0224137-A2 | Process for forming positive tonable images using a photosensitive material containing at least one 1,4-dihydropyridine | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-06-03 | — | — | EP | disclosed |
| US-4346162-A | THIO COMPOUNDS IN NONSILVER PHOTGRAPHY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-08-24 | — | — | US | disclosed |
| US-4292394-A | Process for preparing multicolor toned images on a single photosensitive layer | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-09-29 | — | — | US | disclosed |
| US-4275140-A | HAVING TACKY AREAS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003516-A1 | Compounds, compositions and methods for the treatment of poxvirus infections | IFNG, POLI, STING1 | ALDH1A1 3014/4885LMNA 2309/4885HPGD 873/4885 |
| US-20110015149-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS | ACE, CYP27A1, LIPC | ALDH1A1 857/4885LMNA 2125/4885HPGD 729/4885 |
| US-20070003608-A1 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | ACE, CYP27A1, LIPC | ALDH1A1 857/4885LMNA 2125/4885HPGD 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.